tegafur has been researched along with Alopecia in 14 studies
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 9.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 9.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 7.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 5.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 5.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 3.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| "Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)." | 2.74 | Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. ( Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| " The adverse effects observed were grade 3 leukopenia in 2 patients (11." | 1.33 | [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]. ( Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006) |
| " In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day." | 1.29 | [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. ( Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 1 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 1 |
| Koike, K | 1 |
| Surmont, V | 1 |
| Aerts, JG | 1 |
| Pouw, E | 1 |
| Tan, KY | 1 |
| Vernhout, R | 1 |
| Gras, J | 1 |
| Salomé, J | 1 |
| Pronk, T | 1 |
| Schmitz, PI | 1 |
| Hoogsteden, H | 1 |
| van Klaveren, RJ | 1 |
| Takahashi, I | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Oki, E | 1 |
| Watanabe, M | 1 |
| Baba, H | 1 |
| Maehara, Y | 2 |
| Ishida, H | 2 |
| Akita, H | 1 |
| Watanabe, Y | 1 |
| Nakaguchi, K | 1 |
| Kabuto, T | 1 |
| Hokita, S | 2 |
| Aikou, T | 2 |
| Ishigami, S | 2 |
| Miyazono, F | 2 |
| Nakajo, A | 2 |
| Uenosono, Y | 1 |
| Hamanoue, M | 2 |
| Aridome, K | 2 |
| Natsugoe, S | 2 |
| Komatsu, Y | 1 |
| Yuki, S | 1 |
| Tateyama, M | 1 |
| Kudo, M | 1 |
| Asaka, M | 1 |
| Kodama, T | 1 |
| Okino, T | 1 |
| Okamoto, R | 1 |
| Takahashi, H | 1 |
| Hayashi, N | 1 |
| Mori, K | 1 |
| Noguchi, M | 1 |
| Hatori, S | 1 |
| Kunisaki, C | 1 |
| Ono, H | 1 |
| Sato, T | 1 |
| Otsuka, Y | 1 |
| Yamada, R | 1 |
| Ohshima, T | 1 |
| Rino, Y | 1 |
| Imada, T | 1 |
| Etoh, T | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Morita, S | 1 |
| Takiuchi, H | 1 |
| Nakano, S | 1 |
| Sakamoto, J | 1 |
| Salvati, F | 1 |
| Cruciani, AR | 1 |
| De Marinis, A | 1 |
| Nunziati, F | 1 |
| Portalone, L | 1 |
| Inoue, K | 1 |
| Ogawa, M | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 1 |
| Ikeda, K | 1 |
| Nakada, H | 1 |
| Usui, N | 1 |
| Adachi, K | 1 |
| Tada, A | 1 |
| Yamazaki, H | 1 |
| Tashiro, H | 1 |
| Nomura, Y | 1 |
| Ohsaki, A | 1 |
| Hayashi, T | 1 |
| Tanaka, G | 1 |
| Irimura, K | 1 |
| Hirota, T | 1 |
| Ohmae, S | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Diaz-Rubio, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for tegafur and Alopecia
| Article | Year |
|---|---|
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2009 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth | 1994 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
5 other studies available for tegafur and Alopecia
| Article | Year |
|---|---|
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop | 2006 |
[A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administ | 2006 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administrat | 2006 |
Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Br | 1984 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 1996 |